8-K Announcements
6Material company update
Feb 23, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Nov 19, 2025·SEC
Gilead Sciences, Inc.(GILD)Earnings, Financials & Key Ratios
GILD•NASDAQ
$133.48
$166.32B mkt cap·351.3× P/E·Price updated May 6, 2026
AboutGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.Show more
- Revenue$28.75B+6.0%
- EBITDA$4.43B-57.0%
- Net Income$480M-91.5%
- EPS (Diluted)0.38-91.6%
- Gross Margin78.26%+2.9%
- EBITDA Margin15.4%-59.4%
- Operating Margin5.78%-79.4%
- Net Margin1.67%-92.0%
- ROE2.29%-91.1%
- ROIC3.21%-76.7%
- Debt/Equity1.39+26.4%
- Interest Coverage1.70-78.9%
GILD Key Insights
Gilead Sciences, Inc. (GILD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 35.8% free cash flow margin
- ✓10 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Good 3Y average ROE of 16.6%
- ✓Healthy dividend yield of 2.3%
✗Weaknesses
- ✗Profits declining 38.3% over 5 years
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GILD Price & Volume
Gilead Sciences, Inc. (GILD) stock price & volume — 10-year historical chart
Loading chart...
GILD Growth Metrics
Gilead Sciences, Inc. (GILD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.45%
5 Years5.08%
3 Years1.74%
TTM2.4%
Profit CAGR
10 Years-27.58%
5 Years-38.34%
3 Years-57.44%
TTM1672.92%
EPS CAGR
10 Years-25.64%
5 Years-38.21%
3 Years-57.44%
TTM1729.73%
Return on Capital
10 Years20.82%
5 Years11.34%
3 Years10.58%
Last Year3.4%
GILD Recent Earnings
Gilead Sciences, Inc. (GILD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 10/12 qtrs (83%)
Q1 2026Latest
Feb 10, 2026EPS
$1.86
Est $1.81
+2.8%
Revenue
$7.9B
Est $7.7B
+3.1%
Q4 2025
Oct 30, 2025EPS
$2.47
Est $2.13
+16.0%
Revenue
$7.8B
Est $7.4B
+4.3%
Q3 2025
Aug 7, 2025EPS
$2.01
Est $1.96
+2.6%
Revenue
$7.1B
Est $7.0B
+1.4%
Q2 2025
Apr 24, 2025EPS
$1.81
Est $1.78
+1.7%
Revenue
$6.7B
Est $6.8B
-2.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 10, 2026 | $1.86vs $1.81+2.8% | $7.9Bvs $7.7B+3.1% |
| Q4 2025 | Oct 30, 2025 | $2.47vs $2.13+16.0% | $7.8Bvs $7.4B+4.3% |
| Q3 2025 | Aug 7, 2025 | $2.01vs $1.96+2.6% | $7.1Bvs $7.0B+1.4% |
| Q2 2025 | Apr 24, 2025 | $1.81vs $1.78+1.7% | $6.7Bvs $6.8B-2.1% |
Based on last 12 quarters of dataView full earnings history →
GILD Peer Comparison
Gilead Sciences, Inc. (GILD) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 AMGN | 177.87B | 329.59 | 23.16 | 9.92% | 20.95% | 89.41% | 4.55% | 6.31 |
 BIIB | 27.92B | 189.13 | 21.42 | 1.39% | 13.92% | 7.55% | 7.34% | 0.38 |
 REGN | 72.97B | 702.33 | 16.93 | 0.99% | 29.65% | 14.32% | 5.59% | 0.09 |
 VRTX | 107.94B | 424.36 | 27.70 | 9.57% | 35.4% | 23.93% | 2.96% | 0.21 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
Compare GILD vs Peers
Gilead Sciences, Inc. (GILD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GILD Income Statement
Gilead Sciences, Inc. (GILD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 30.39B | 26.11B | 22.13B | 22.45B | 24.69B | 27.3B | 27.28B | 27.12B | 28.75B | 29.44B |
| Revenue Growth % | -6.89% | -14.09% | -15.25% | 1.46% | 9.98% | 10.6% | -0.09% | -0.6% | 6.04% | 2.4% |
| Cost of Goods Sold | 4.26B | 4.37B | 4.85B | 4.67B | 4.57B | 6.6B | 5.66B | 6.5B | 6.25B | 5.65B |
| COGS % of Revenue | 14.02% | 16.74% | 21.93% | 20.82% | 18.52% | 24.18% | 20.74% | 23.96% | 21.74% | - |
| Gross Profit | 26.13B▲ 0% | 21.74B▼ 16.8% | 17.27B▼ 20.5% | 17.77B▲ 2.9% | 20.12B▲ 13.2% | 20.7B▲ 2.9% | 21.62B▲ 4.4% | 20.62B▼ 4.7% | 22.5B▲ 9.1% | 23.79B▲ 0% |
| Gross Margin % | 85.98% | 83.26% | 78.07% | 79.17% | 81.48% | 75.82% | 79.26% | 76.04% | 78.26% | 80.8% |
| Gross Profit Growth % | -8.75% | -16.81% | -20.53% | 2.89% | 13.18% | 2.92% | 4.44% | -4.65% | 9.14% | - |
| Operating Expenses | 8.5B | 7.61B | 7.98B | 8.44B | 16.05B | 10.79B | 14.29B | 13.01B | 20.84B | 12.79B |
| OpEx % of Revenue | 27.96% | 29.16% | 36.05% | 37.58% | 64.99% | 39.5% | 52.4% | 47.99% | 72.48% | - |
| Selling, General & Admin | 3.4B | 3.88B | 4.06B | 4.38B | 5.11B | 5.25B | 5.67B | 6.09B | 6.09B | 5.76B |
| SG&A % of Revenue | 11.18% | 14.85% | 18.33% | 19.52% | 20.71% | 19.21% | 20.79% | 22.46% | 21.18% | - |
| Research & Development | 5.1B | 3.73B | 3.92B | 4.05B | 5.04B | 4.6B | 4.98B | 5.72B | 5.91B | 5.78B |
| R&D % of Revenue | 16.78% | 14.3% | 17.72% | 18.06% | 20.41% | 16.85% | 18.24% | 21.09% | 20.54% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 5.89B | 939M | 3.64B | 1.21B | 8.84B | 4M |
| Operating Income | 17.63B▲ 0% | 14.12B▼ 19.9% | 8.2B▼ 41.9% | 4.29B▼ 47.7% | 4.07B▼ 5.0% | 9.92B▲ 143.6% | 7.33B▼ 26.1% | 7.61B▲ 3.8% | 1.66B▼ 78.1% | 11B▲ 0% |
| Operating Margin % | 58.02% | 54.1% | 37.06% | 19.1% | 16.49% | 36.32% | 26.87% | 28.05% | 5.78% | 37.37% |
| Operating Income Growth % | -20.55% | -19.9% | -41.94% | -47.72% | -5.04% | 143.63% | -26.09% | 3.75% | -78.15% | - |
| EBITDA | 18.79B | 15.41B | 9.63B | 5.69B | 5.55B | 11.97B | 9.43B | 10.3B | 4.43B | 12.45B |
| EBITDA Margin % | 61.83% | 59.03% | 43.52% | 25.35% | 22.48% | 43.83% | 34.58% | 37.98% | 15.4% | 42.27% |
| EBITDA Growth % | -19.32% | -17.99% | -37.51% | -40.9% | -2.46% | 115.6% | -21.18% | 9.17% | -56.99% | 180.99% |
| D&A (Non-Cash Add-back) | 1.16B | 1.29B | 1.43B | 1.4B | 1.48B | 2.05B | 2.1B | 2.69B | 2.77B | 2.07B |
| EBIT | 18.06B | 14.65B | 8.88B | 6.16B | 2.65B | 9.28B | 6.75B | 7.8B | 1.67B | 10.82B |
| Net Interest Income | -964M | -1.12B | -1.08B | -995M | -984M | -1B | -829M | -568M | -696M | -770M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 106M | 376M | 281M | 255M |
| Interest Expense | 964M | 1.12B | 1.08B | 995M | 984M | 1B | 935M | 944M | 977M | 1.02B |
| Other Income/Expense | -536M | -595M | -401M | 873M | -2.4B | -1.64B | -1.52B | -746M | -972M | -1.21B |
| Pretax Income | 17.1B▲ 0% | 13.53B▼ 20.9% | 7.8B▼ 42.4% | 5.16B▼ 33.8% | 1.67B▼ 67.7% | 8.28B▲ 396.0% | 5.81B▼ 29.8% | 6.86B▲ 18.0% | 690M▼ 89.9% | 9.8B▲ 0% |
| Pretax Margin % | 56.26% | 51.82% | 35.25% | 22.99% | 6.76% | 30.32% | 21.31% | 25.3% | 2.4% | 33.28% |
| Income Tax | 3.61B | 8.88B | 2.34B | -204M | 1.58B | 2.08B | 1.25B | 1.25B | 211M | 1.29B |
| Effective Tax Rate % | 21.11% | 65.67% | 29.99% | -3.95% | 94.67% | 25.09% | 21.47% | 18.18% | 30.58% | 13.13% |
| Net Income | 13.5B▲ 0% | 4.63B▼ 65.7% | 5.46B▲ 17.9% | 5.39B▼ 1.3% | 123M▼ 97.7% | 6.22B▲ 4961.0% | 4.59B▼ 26.2% | 5.67B▲ 23.4% | 480M▼ 91.5% | 8.51B▲ 0% |
| Net Margin % | 44.43% | 17.73% | 24.65% | 23.99% | 0.5% | 22.8% | 16.83% | 20.89% | 1.67% | 28.9% |
| Net Income Growth % | -25.44% | -65.72% | 17.87% | -1.26% | -97.72% | 4960.98% | -26.23% | 23.37% | -91.53% | 1672.92% |
| Net Income (Continuing) | 13.49B | 4.64B | 5.46B | 5.36B | 89M | 6.2B | 4.57B | 5.61B | 479M | 8.51B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 476M | 59M | 147M | 125M | 19M | -5M | -31M | -84M | -84M | 0 |
| EPS (Diluted) | 9.94▲ 0% | 3.51▼ 64.7% | 4.17▲ 18.8% | 4.22▲ 1.2% | 0.10▼ 97.7% | 4.93▲ 4961.6% | 3.64▼ 26.2% | 4.50▲ 23.6% | 0.38▼ 91.6% | 6.79▲ 0% |
| EPS Growth % | -16.54% | -64.69% | 18.8% | 1.2% | -97.69% | 4961.6% | -26.17% | 23.63% | -91.56% | 1729.73% |
| EPS (Basic) | 10.08 | 3.54 | 4.20 | 4.24 | 0.10 | 4.96 | 3.66 | 4.54 | 0.38 | - |
| Diluted Shares Outstanding | 1.36B | 1.32B | 1.31B | 1.28B | 1.26B | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B |
| Basic Shares Outstanding | 1.34B | 1.31B | 1.3B | 1.27B | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B | 1.24B |
| Dividend Payout Ratio | 18.18% | 59.01% | 54.46% | 59.82% | 2804.07% | 57.91% | 80.77% | 67.24% | 816.25% | - |
GILD Balance Sheet
Gilead Sciences, Inc. (GILD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 19.59B | 31.82B | 35.84B | 30.3B | 16B | 14.77B | 14.44B | 16.09B | 19.17B | 19.89B |
| Cash & Short-Term Investments | 11.89B | 25.51B | 30.09B | 24.35B | 7.41B | 6.52B | 6.38B | 7.26B | 11.57B | 10.61B |
| Cash Only | 8.23B | 7.59B | 17.94B | 11.63B | 6B | 5.34B | 5.41B | 6.08B | 9.99B | 0 |
| Short-Term Investments | 3.67B | 17.92B | 12.15B | 12.72B | 1.41B | 1.18B | 973M | 1.18B | 1.58B | 10.61B |
| Accounts Receivable | 4.51B | 3.85B | 3.33B | 3.58B | 4.89B | 4.49B | 4.78B | 4.66B | 4.42B | 4.91B |
| Days Sales Outstanding | 54.22 | 53.84 | 54.88 | 58.24 | 72.32 | 60.06 | 63.91 | 62.73 | 56.11 | 59.44 |
| Inventory | 1.59B | 801M | 814M | 922M | 1.68B | 1.62B | 1.51B | 1.79B | 1.71B | 4.37B |
| Days Inventory Outstanding | 135.94 | 66.89 | 61.22 | 71.98 | 134.36 | 89.47 | 97.23 | 100.38 | 99.85 | 157.17 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.37B | 995M | 0 |
| Total Non-Current Assets | 37.39B | 38.46B | 27.84B | 31.33B | 52.41B | 53.18B | 48.73B | 46.04B | 39.82B | 39.14B |
| Property, Plant & Equipment | 2.87B | 3.29B | 4.01B | 4.5B | 4.97B | 5.12B | 5.47B | 5.32B | 5.41B | 5.61B |
| Fixed Asset Turnover | 10.61x | 7.92x | 5.52x | 4.99x | 4.97x | 5.33x | 4.98x | 5.10x | 5.31x | 5.36x |
| Goodwill | 1.17B | 4.16B | 4.12B | 4.12B | 8.11B | 8.33B | 8.31B | 8.31B | 8.31B | 8.31B |
| Intangible Assets | 8.97B | 17.1B | 15.74B | 13.79B | 33.13B | 33.45B | 28.89B | 26.45B | 19.95B | 16.98B |
| Long-Term Investments | 20.48B | 11.18B | 1.42B | 1.49B | 502M | 1.31B | 1.25B | 1.16B | 0 | 4.6B |
| Other Non-Current Assets | 3.49B | 2.72B | 2.56B | 7.44B | 5.71B | 4.96B | 4.8B | 4.79B | 6.15B | 20.33B |
| Total Assets | 56.98B▲ 0% | 70.28B▲ 23.4% | 63.67B▼ 9.4% | 61.63B▼ 3.2% | 68.41B▲ 11.0% | 67.95B▼ 0.7% | 63.17B▼ 7.0% | 62.13B▼ 1.7% | 58.99B▼ 5.0% | 59.02B▲ 0% |
| Asset Turnover | 0.53x | 0.37x | 0.35x | 0.36x | 0.36x | 0.40x | 0.43x | 0.44x | 0.49x | 0.51x |
| Asset Growth % | 10.17% | 23.35% | -9.4% | -3.22% | 11% | -0.67% | -7.04% | -1.66% | -5.04% | 11.65% |
| Total Current Liabilities | 9.22B | 11.63B | 10.61B | 9.76B | 11.4B | 11.61B | 11.24B | 11.28B | 12B | 11.81B |
| Accounts Payable | 1.21B | 814M | 790M | 713M | 844M | 705M | 905M | 550M | 833M | 0 |
| Days Payables Outstanding | 103.31 | 67.97 | 59.42 | 55.67 | 67.38 | 38.98 | 58.39 | 30.89 | 48.64 | 34.33 |
| Short-Term Debt | 0 | 2.75B | 2.75B | 2.5B | 2.76B | 1.52B | 2.27B | 1.8B | 1.81B | 0 |
| Deferred Revenue (Current) | 202M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 196M | 455M | 555M | 736M | 1.45B | 1.43B | 3.62B | 3.92B | 3.82B | 11.81B |
| Current Ratio | 2.12x | 2.74x | 3.38x | 3.10x | 1.40x | 1.27x | 1.29x | 1.43x | 1.60x | 1.60x |
| Quick Ratio | 1.95x | 2.67x | 3.30x | 3.01x | 1.26x | 1.13x | 1.15x | 1.27x | 1.45x | 1.45x |
| Cash Conversion Cycle | 86.85 | 52.76 | 56.69 | 74.56 | 139.3 | 110.54 | 102.75 | 132.21 | 107.32 | 182.28 |
| Total Non-Current Liabilities | 28.4B | 38.15B | 31.54B | 29.22B | 38.79B | 35.28B | 30.72B | 28.1B | 27.75B | 24.59B |
| Long-Term Debt | 26.35B | 30.8B | 24.57B | 22.09B | 28.64B | 25.18B | 22.96B | 23.19B | 24.9B | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.91B | 4.36B | 2.67B | 1.59B | 724M | 1.96B |
| Other Non-Current Liabilities | 2.05B | 7.35B | 6.96B | 7.12B | 6.23B | 5.74B | 5.09B | 3.32B | 2.13B | 30.95B |
| Total Liabilities | 37.61B | 49.78B | 42.14B | 38.98B | 50.19B | 46.89B | 41.96B | 39.38B | 39.75B | 36.41B |
| Total Debt | 26.35B | 33.54B | 27.32B | 24.59B | 31.4B | 26.7B | 25.23B | 24.99B | 26.71B | 0 |
| Net Debt | 18.12B | 25.95B | 9.38B | 12.96B | 25.41B | 21.36B | 19.82B | 18.9B | 16.72B | 0 |
| Debt / Equity | 1.36x | 1.64x | 1.27x | 1.09x | 1.72x | 1.27x | 1.19x | 1.10x | 1.39x | 1.39x |
| Debt / EBITDA | 1.40x | 2.18x | 2.84x | 4.32x | 5.66x | 2.23x | 2.67x | 2.43x | 6.03x | 0.00x |
| Net Debt / EBITDA | 0.96x | 1.68x | 0.97x | 2.28x | 4.58x | 1.78x | 2.10x | 1.84x | 3.78x | 3.78x |
| Interest Coverage | 18.29x | 12.63x | 7.61x | 4.31x | 4.14x | 9.91x | 7.84x | 8.06x | 1.70x | 10.56x |
| Total Equity | 19.36B▲ 0% | 20.5B▲ 5.9% | 21.53B▲ 5.0% | 22.65B▲ 5.2% | 18.22B▼ 19.6% | 21.06B▲ 15.6% | 21.21B▲ 0.7% | 22.75B▲ 7.3% | 19.25B▼ 15.4% | 22.62B▲ 0% |
| Equity Growth % | 1.31% | 5.88% | 5.04% | 5.18% | -19.55% | 15.6% | 0.69% | 7.26% | -15.4% | 51.15% |
| Book Value per Share | 14.26 | 15.54 | 16.46 | 17.74 | 14.43 | 16.69 | 16.81 | 18.08 | 15.34 | 18.05 |
| Total Shareholders' Equity | 18.89B | 20.44B | 21.39B | 22.52B | 18.2B | 21.07B | 21.24B | 22.83B | 19.33B | 22.62B |
| Common Stock | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 1M | 0 |
| Retained Earnings | 18.15B | 19.01B | 19.02B | 19.39B | 14.38B | 16.32B | 15.69B | 16.3B | 11.5B | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 278M | 165M | 80M | 85M | -60M | 83M | 2M | 28M | 132M | 0 |
| Minority Interest | 476M | 59M | 147M | 125M | 19M | -5M | -31M | -84M | -84M | 0 |
GILD Cash Flow Statement
Gilead Sciences, Inc. (GILD) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 17.05B | 11.9B | 8.4B | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B | 10.83B | 10.83B |
| Operating CF Margin % | 56.09% | 45.57% | 37.96% | 40.73% | 33.08% | 41.69% | 33.25% | 29.53% | 37.66% | - |
| Operating CF Growth % | -19.78% | -30.2% | -29.4% | 8.86% | -10.67% | 39.37% | -20.31% | -11.75% | 35.25% | -51.27% |
| Net Income | 13.49B | 4.64B | 5.46B | 5.36B | 123M | 6.2B | 4.59B | 5.67B | 480M | 8.51B |
| Depreciation & Amortization | 1.16B | 1.29B | 1.43B | 1.4B | 1.48B | 2.05B | 2.1B | 2.69B | 2.77B | 2.07B |
| Stock-Based Compensation | 380M | 638M | 845M | 636M | 643M | 635M | 644M | 766M | 835M | 664M |
| Deferred Taxes | -119M | -82M | 289M | -2.1B | -214M | -116M | -1.55B | -962M | -1.84B | 282M |
| Other Non-Cash Items | 594M | 304M | 1.32B | 4.64B | 7.77B | 2.13B | 5.05B | 2.15B | 9.47B | -4.49B |
| Working Capital Changes | 1.55B | 5.11B | -939M | -798M | -1.64B | 489M | -1.76B | -2.3B | -880M | -3.34B |
| Change in Receivables | 1.19B | 754M | 480M | -218M | -1.17B | 313M | -406M | 157M | 139M | -546M |
| Change in Inventory | -488M | -253M | -310M | -95M | -195M | 11M | -310M | -842M | -426M | -913M |
| Change in Payables | 47M | -430M | -39M | -61M | 80M | -118M | 226M | -347M | 290M | -37M |
| Cash from Investing | -11.98B | -16.07B | 14.36B | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B | -3.45B | -4.79B |
| Capital Expenditures | -748M | -590M | -924M | -825M | -650M | -579M | -728M | -585M | -523M | -358M |
| CapEx % of Revenue | 2.46% | 2.26% | 4.18% | 3.67% | 2.63% | 2.12% | 2.67% | 2.16% | 1.82% | - |
| Acquisitions | 0 | -10.43B | 0 | -4.25B | -25.74B | -1.58B | -1.8B | -1.15B | -4.84B | -461M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -190M | -434M | -171M | 19M | -1M | 0 | 58M | -1.84B |
| Cash from Financing | -9.72B | 3.39B | -12.32B | -7.63B | 770M | -8.88B | -6.47B | -5.13B | -3.43B | -7.75B |
| Debt Issued (Net) | 4.27B | 7.17B | -6.25B | -2.75B | 5.68B | -4.75B | -1.5B | -270M | 1.49B | -1.78B |
| Equity Issued (Net) | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -3M |
| Dividends Paid | -2.46B | -2.73B | -2.97B | -3.22B | -3.45B | -3.6B | -3.71B | -3.81B | -3.92B | -3.01B |
| Share Repurchases | -11B | -954M | -2.9B | -1.75B | -1.58B | -546M | -1.4B | -1B | -1.15B | -1.69B |
| Other Financing | -745M | -330M | -486M | -122M | -138M | -145M | -173M | -278M | -281M | -1.64B |
| Net Change in Cash | -4.62B▲ 0% | -641M▲ 86.1% | 10.35B▲ 1715.0% | -6.31B▼ 160.9% | -5.63B▲ 10.7% | -659M▲ 88.3% | 74M▲ 111.2% | 673M▲ 809.5% | 3.91B▲ 480.4% | -2.43B▲ 0% |
| Free Cash Flow | 16.3B▲ 0% | 11.31B▼ 30.6% | 7.48B▼ 33.9% | 8.32B▲ 11.3% | 7.52B▼ 9.6% | 10.8B▲ 43.7% | 8.34B▼ 22.8% | 7.42B▼ 11.1% | 10.3B▲ 38.9% | 9.66B▲ 0% |
| FCF Margin % | 53.63% | 43.31% | 33.79% | 37.06% | 30.45% | 39.57% | 30.59% | 27.37% | 35.84% | 32.81% |
| FCF Growth % | -20.5% | -30.62% | -33.89% | 11.28% | -9.63% | 43.72% | -22.78% | -11.06% | 38.86% | -6.26% |
| FCF per Share | 12.00 | 8.57 | 5.72 | 6.51 | 5.95 | 8.56 | 6.61 | 5.90 | 8.21 | 8.21 |
| FCF Conversion (FCF/Net Income) | 1.26x | 2.57x | 1.54x | 1.70x | 66.41x | 1.83x | 1.98x | 1.41x | 22.56x | 1.14x |
| Interest Paid | 885M | 1.04B | 1.07B | 982M | 951M | 979M | 907M | 891M | 951M | 0 |
| Taxes Paid | 2.44B | 3.34B | 3.2B | 1.79B | 2.64B | 2.51B | 3.14B | 3.99B | 2.78B | 0 |
GILD Key Ratios
Gilead Sciences, Inc. (GILD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 70.18% | 23.22% | 25.95% | 24.38% | 0.6% | 31.69% | 21.73% | 25.77% | 2.29% | 37.62% |
| Return on Invested Capital (ROIC) | 40.2% | 25.24% | 15.9% | 9.67% | 7.71% | 17.29% | 13.18% | 13.8% | 3.21% | 3.21% |
| Gross Margin | 85.98% | 83.26% | 78.07% | 79.17% | 81.48% | 75.82% | 79.26% | 76.04% | 78.26% | 80.8% |
| Net Margin | 44.43% | 17.73% | 24.65% | 23.99% | 0.5% | 22.8% | 16.83% | 20.89% | 1.67% | 28.9% |
| Debt / Equity | 1.36x | 1.64x | 1.27x | 1.09x | 1.72x | 1.27x | 1.19x | 1.10x | 1.39x | 1.39x |
| Interest Coverage | 18.29x | 12.63x | 7.61x | 4.31x | 4.14x | 9.91x | 7.84x | 8.06x | 1.70x | 10.56x |
| FCF Conversion | 1.26x | 2.57x | 1.54x | 1.70x | 66.41x | 1.83x | 1.98x | 1.41x | 22.56x | 1.14x |
| Revenue Growth | -6.89% | -14.09% | -15.25% | 1.46% | 9.98% | 10.6% | -0.09% | -0.6% | 6.04% | 2.4% |
GILD SEC Filings & Documents
Gilead Sciences, Inc. (GILD) SEC filings — annual & quarterly reports (10-K, 10-Q)
GILD Frequently Asked Questions
Gilead Sciences, Inc. (GILD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gilead Sciences, Inc. (GILD) reported $29.44B in revenue for fiscal year 2024. This represents a 1090344% increase from $2.7M in 1995.
Gilead Sciences, Inc. (GILD) grew revenue by 6.0% over the past year. This is steady growth.
Yes, Gilead Sciences, Inc. (GILD) is profitable, generating $8.51B in net income for fiscal year 2024 (1.7% net margin).
Dividend & Returns
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a yield of 2.34%. This makes it attractive for income-focused investors.
Gilead Sciences, Inc. (GILD) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
Gilead Sciences, Inc. (GILD) generated $9.66B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More GILD
Gilead Sciences, Inc. (GILD) financial analysis — history, returns, DCA and operating performance tools
Full GILD Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates